News

InCarda Therapeutics to Present Preliminary Phase 2 Data at American Heart Association 2020 Scientific Sessions (Nov. 13-17, 2020)

On Friday, November 13 at 9:00am CT/10:00am ET, Dr. Harry Crijns, Clinical Electrophysiologist from Maastricht University Medical Center in the Netherlands, will present data from the open-label, dose-escalation Part A portion of InCarda’s multinational INSTANT Phase 2 clinical trial of InRhythm™ (flecainide for inhalation) in...

InCarda Therapeutics featured in Endpoints News

InCarda Therapeutics and our President & CEO Grace Colón were featured in a recent post on Endpoints News. The post highlights InCarda's Raise of $30 Million Through First Close of Series C Equity Financing. More information below: “This is especially exciting at a time when more...

InCarda Therapeutics featured in FierceBiotech News

InCarda Therapeutics and our President & CEO Grace Colón were featured in a recent post on Endpoints News. The post highlights InCarda's Raise of $30 Million Through First Close of Series C Equity Financing. More information below: “What we're doing is a completely new way of...

Grace Colón joins the Biotech2050 podcast

Biotech2050 podcast which aired 6/18/2020 featuring our President and CEO Grace Colon! She shares how her passion for #engineering and #biotech lead to our breakthrough approach to treat #AFib. Hear our story here: https://bit.ly/37wTDN9 #WomenInSTEM #cardiovascular #clinicaltrials #medicaldevice #biotech #startup...

InCarda’s CEO Grace Colon presented at Bio Digital Week 2020

Our CEO Grace Colón moderated the "Digital Health in Respiratory Care – The Next Frontier" panel at Bio Digital Week 2020. More information below: While most of the attention in the use of digital health for chronic care management has gone to players in the diabetes,...